<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893317</url>
  </required_header>
  <id_info>
    <org_study_id>CS-098</org_study_id>
    <nct_id>NCT04893317</nct_id>
  </id_info>
  <brief_title>Cryoablation for Monomorphic Ventricular Tachycardia</brief_title>
  <acronym>CryoCure VT</acronym>
  <official_title>Cryoablation for Monomorphic Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagio Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagio Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm, multi-center, pre-market, clinical study designed to provide&#xD;
      safety and performance data regarding the use of the Adagio System in the treatment of&#xD;
      ventricular tachycardia.&#xD;
&#xD;
      Study subjects will include patients who experience recurrent monomorphic VT and are&#xD;
      scheduled for an endocardial VT ablation. Study subjects have or will have an Implantable&#xD;
      Cardioverter Defibrillator (ICD) prior to hospital discharge following the cryoablation&#xD;
      procedure.&#xD;
&#xD;
      A VT ablation procedure is performed by finding the abnormal ventricular heart tissue that is&#xD;
      causing the VT and applying energy with an ablation catheter to the area. The goal is to&#xD;
      apply energy to create a scar or destroy the tissue that causes the VT, such that VT is no&#xD;
      longer present or inducible.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An analysis of the proportion of subjects who are free from definite or probable device/procedure related Major Adverse Events (MAEs) that occur during or within 30 days following the cryoablation procedure</measure>
    <time_frame>30 days following the cryoablation procedure</time_frame>
    <description>MAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>An analysis of the proportion of patients receiving a single cryoablation procedure with freedom from ventricular tachycardia lasting longer than 30 seconds after the 3-Month blanking period until the end of the 6 month follow up period.</measure>
    <time_frame>6 month</time_frame>
    <description>Freedom from ventricular tachycardia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>An analysis of the proportion of subjects with non-inducible monomorphic VT at the conclusion of the initial cryotherapy ablation procedure.</measure>
    <time_frame>12 months</time_frame>
    <description>non-inducible monomorphic VT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: The proportion of study subjects with probable or definite device or procedure related serious adverse events (SAEs) including MAEs as described above, or serious adverse device effects (SADEs) between 30-days up to 12 months post-procedure.</measure>
    <time_frame>12 months</time_frame>
    <description>Serious adverse events (SAEs) including MAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance: The proportion of study subjects with freedom from Ventricular Tachycardia lasting longer than 30 seconds at 12 months without the use of anti-arrhythmic drugs (AADs)</measure>
    <time_frame>12 months</time_frame>
    <description>freedom from Ventricular Tachycardia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Monomorphic Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Ablation in the ventricle with the Adagio VT cryoablation system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation in the ventricles with cryoablation</intervention_name>
    <description>The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias</description>
    <arm_group_label>Ablation in the ventricle with the Adagio VT cryoablation system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female the ages of â‰¥ 18 years&#xD;
&#xD;
          -  Suitable for a catheter ablation due to Ischemic and/or non-ischemic symptomatic&#xD;
             monomorphic Ventricular Tachycardia, also monomorphic is defined as a similar QRS&#xD;
             configuration from beat to beat.&#xD;
&#xD;
          -  Has or will be receiving an ICD prior to hospital discharge post procedure.&#xD;
&#xD;
          -  Scheduled for a de novo VT ablation and refractory to at least one AAD, based on&#xD;
             physician discretion and hospital standards (Refractory is defined as an AAD not able&#xD;
             to treat the arrhythmia satisfactorily or inducing unwanted side effects).&#xD;
&#xD;
          -  Subject has LVEF &gt; 20%, confirmed by echo or comparable technique during baseline&#xD;
             evaluation&#xD;
&#xD;
          -  Willingness, ability, and commitment to participate in baseline and follow-up&#xD;
             evaluations for the full length of the study&#xD;
&#xD;
          -  Willingness and ability to give an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the Investigator, any known contraindication to a ventricular&#xD;
             tachycardia ablation, TEE, or anticoagulation, including but not limited to the&#xD;
             identification of any cardiac thrombus or evidence of sepsis&#xD;
&#xD;
          -  Any duration of continuous arrythmia that is not monomorphic ventricular tachycardia.&#xD;
             Multiple mono morphic tachycardia is acceptable, but poly morphic VT is not.&#xD;
&#xD;
          -  History of previous ablation or surgical treatment for ventricular tachycardia&#xD;
&#xD;
          -  Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or&#xD;
             any other reversible or non-cardiac cause&#xD;
&#xD;
          -  Structural heart disease as described below:&#xD;
&#xD;
               1. Aortic aneurysm&#xD;
&#xD;
               2. Previous cardiac surgery, ventriculotomy or atriotomy (excluding atriotomy for&#xD;
                  CABG),&#xD;
&#xD;
               3. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve&#xD;
&#xD;
               4. Interatrial baffle, closure device, patch, or PFO occlusion device&#xD;
&#xD;
               5. IVC filter&#xD;
&#xD;
               6. Coronary artery bypass graft (CABG) procedure within six (6) months prior to the&#xD;
                  ablation procedure&#xD;
&#xD;
               7. Unstable angina or ongoing myocardial ischemia&#xD;
&#xD;
               8. Severe Mitral or Aortic insufficiency or stenosis based on most recent TTE&#xD;
&#xD;
               9. Cardiac myxoma&#xD;
&#xD;
              10. Significant congenital anomaly&#xD;
&#xD;
              11. Recent Myocardial Infarct (MI) or unstable angina, within 60 days prior to the&#xD;
                  ablation procedure&#xD;
&#xD;
          -  Any previous history of cryoglobulinemia&#xD;
&#xD;
          -  History of blood clotting or bleeding disease&#xD;
&#xD;
          -  Any prior history of documented cerebral vascular accident (CVA), TIA or systemic&#xD;
             embolism (excluding a post-operative DVT), within 6 months.&#xD;
&#xD;
          -  Pregnant, anticipated during study follow-up&#xD;
&#xD;
          -  Current enrollment in any other study protocol where testing or results from that&#xD;
             study may interfere with the procedure or outcome measurements for this study&#xD;
&#xD;
          -  Any other condition that, in the judgment of the investigator, makes the patient a&#xD;
             poor candidate for this procedure, the study or compliance with the protocol (includes&#xD;
             vulnerable patient population, mental illness, addictive disease, terminal illness&#xD;
             with a minimal life expectancy as it pertains to follow up)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom DE POTTER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OLV Ziekenhuis; Aalst-Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Didier BILLY, PhD</last_name>
    <phone>+31654954128</phone>
    <email>dbilly@adagiomedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nabil JUBRAN</last_name>
    <phone>+1 949-348-1188</phone>
    <phone_ext>207</phone_ext>
    <email>njubran@adagiomedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onze Lieve Vrouwziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom DE POTTER, MD</last_name>
      <phone>+3253724168</phone>
      <email>tom.de.potter@olvz-aalst.bet.be</email>
    </contact>
    <contact_backup>
      <last_name>Hedwig BATJOENS</last_name>
      <phone>+3253724168</phone>
      <email>hedwig.batjoens@olvz-aalst.be</email>
    </contact_backup>
    <investigator>
      <last_name>Tom De Potter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

